Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
회사 코드SNY
회사 이름Sanofi SA
상장일Jul 01, 2002
설립일1994
CEOMr. Paul Hudson, Ph.D.
직원 수84587
유형Depository Receipt
회계 연도 종료Jul 01
주소46 Avenue de la Grande Armee
도시PARIS
증권 거래소NASDAQ Global Select Consolidated
국가France
우편 번호75017
전화33153774000
웹사이트https://www.sanofi.com/
회사 코드SNY
상장일Jul 01, 2002
설립일1994
지난 5년 동안 총
23.51B
USD의 배당금이 분배되었습니다.
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020